《NEJM》重磅发表：Beamion LUNG-1 宗艾替尼一线治疗 HER2 突变晚期 NSCLC研究结果公布

整理：肿瘤资讯

来源：肿瘤资讯

HER2（ERBB2）基因突变见于2%-4%的非小细胞肺癌（NSCLC），这类患者疾病侵袭性强、预后差，脑转移发生率高，是肺癌精准治疗领域长期未被攻克的难点^{[1, 2]}。长期以来，HER2突变NSCLC始终未能迎来专属的一线靶向治疗方案，患者的临床需求远未被满足^[1]。2026年4月15日，Beamion LUNG-1研究中高选择性HER2酪氨酸激酶抑制剂（TKI）宗艾替尼（Zongertinib）一线治疗HER2突变晚期NSCLC的核心结果，全文在线发表于国际顶级医学期刊《新英格兰医学杂志》（NEJM）^[1]。该研究证实，宗艾替尼单药一线治疗能为HER2突变晚期NSCLC患者带来显著且持久的肿瘤缓解与生存获益，同时兼具良好的安全性^[1]，基于此研究成果，宗艾替尼获FDA批准用于HER2酪氨酸激酶结构域突变晚期NSCLC一线治疗适应症，填补了该领域一线无靶向治疗方案的空白。值此之际，特邀该研究作者之一、河南省肿瘤医院赵艳秋教授，深度解读这项里程碑式研究的核心价值、临床启示与实践意义。

专家简介

赵艳秋教授

主任医师，二级教授
河南省肿瘤医院内科副主任
河南省肿瘤医院肺癌首席专家组成员
中国临床肿瘤学会（CSCO）小细胞肺癌专委会委员
河南省生命关怀协会肺癌专业委员会主委
作为PI参与肺癌相关临床试验100多项

审批号：SC-CN-18663

有效期至2027年5月18日

仅供相关医学人士进行医学科学交流

参考文献

[1] Heymach JV, Yamamoto N, Girard N, et al. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026. 394(17): 1675-1684.

[2] Heymach JV, Opdam F, Barve M, et al. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. J Clin Oncol. 2025. 43(11): 1337-1347.

[3] Offin M, Feldman D, Ni A, et al. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. Cancer. 2019. 125(24): 4380-4387.

[4] Lin JJ, Gainor JF. Time to tackle the blood-brain barrier in HER2-mutant lung cancer. Cancer. 2019. 125(24): 4363-4366.

[5] Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016. 45: 139-62.

[6] John V. Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al. Zongertinib in patients with pretreated HER2-mutant advanced NSCLC: Beamion LUNG-1. 2025 AACR. CT050 .

[7] Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025. 392(23): 2321-2333.

[8] Yi-Long Wu, Hai-Yan Tu, Yan Yu, et al. Zongertinib in Asian patients with previously treated advanced HER2-mutant NSCLC. 2025 ESMO Asia. 975MO .

[9] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non Small Cell Lung Cancer. Version 8. 2025 .

[10] 中国临床肿瘤学会（CSCO). CSCO非小细胞肺癌诊疗指南2026 .

[11] Sanjay Popat, Noboru Yamamoto, Nicolas Girard, et al. Zongertinib as First-Line Treatment in Patients with Advanced HER2-Mutant NSCLC: Beamion LUNG-1. 2025 ESMO. LBA74 .

[12] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non Small Cell Lung Cancer. Version 5. 2026 .

[13] John V. Heymach, Noboru Yamamoto, Nicolas Girard, et al. Zongertinib in Treatment-Naïve Patients With HER2-mutant NSCLC, Including Those With Active Brain Metastases: Beamion LUNG-1. 2026 ELCC. 6MO .

责任编辑：肿瘤资讯-明小丽
排版编辑：肿瘤资讯-Awa